Sign in
Taking people in United StatesNo phase

Studies cannabis use and quality of life in people with multiple myeloma

Observes how cannabis use may affect quality of life in adults with myeloma receiving chemotherapy.

Key facts

Who runs it
City of Hope Medical Center
Where
Duarte, Goodyear, Huntington Beach, Irvine, Long Beach, Newnan, Newport Beach, South Pasadena, Upland, West Covina, and Zion, United StatesSee the 11 sites
Trial code
Registry title
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
Status
Recruiting
People taking part
700 people, planned
Started
21 Jan 2026
Expected to end
22 Aug 2030
Type of study
Observational, 2 groups
Treatments tested
  • Non-Interventional Study
Record updated
20 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed multiple myeloma who have had little or no first treatment. It studies how cannabis use affects quality of life. Some health care workers can also join a survey.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Newly diagnosed multiple myeloma, confirmed by tissue examination. ECOG of 3 or lower.
Earlier treatment
Patients may have started first line therapy and had up to four cycles. They must not have completed five cycles of first line therapy or had any second line therapy. They must not have had an autologous stem cell transplant.

Main reasons for not taking part

  • Another active cancer
  • Completed five cycles of first line therapy or had second line therapy
  • Had an autologous stem cell transplant
  • Cannot take part in the study assessments
  • Cannot read and understand English

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • * Documented informed consent of the participant; Age: ≥ 18 years; ECOG ≤ 3; Ability to read and understand English; Patient must be newly diagnosed with a histologically confirmed multiple myeloma; Patients may have started first line therapies and received up to four cycles; HCP SURVEY: Documented informed consent of the participant; HCP SURVEY: Age: ≥ 18 years; HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse; HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients; HCP SURVEY: Able to read and understand English; HCP SURVEY: Affiliation with City of Hope

Who cannot take part

  • * Patients may not have completed five cycles of first line therapy or undergone any second line therapy; Other active malignancy; Patients may not have undergone autologous hematopoietic stem cell transplantation; Unable to comply with the study assessments; HCP SURVEY: Reports directly to study PI (Dr. Richard Lee); HCP SURVEY: Member of the study team or involved in survey design or analysis; HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses

Where in United States

  • City of Hope Medical CenterDuarte, United StatesContact: Richard T. LeeTaking people
  • CTCA at Western Regional Medical CenterGoodyear, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope SeacliffHuntington Beach, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope at Irvine LennarIrvine, United StatesContact: Richard T. LeeTaking people
  • City of Hope at Long Beach ElmLong Beach, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope Atlanta Cancer CenterNewnan, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope at Newport Beach Fashion IslandNewport Beach, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope South PasadenaSouth Pasadena, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope UplandUpland, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope West CovinaWest Covina, United StatesContact: Richard T. LeeNot yet recruiting
  • City of Hope at ChicagoZion, United StatesContact: Richard T. LeeNot yet recruiting

About the trial

What the trial wants to find out

This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.

The 2 groups in the trial

  • Observational group I

    Patients complete surveys and undergo blood sample collection throughout the study.

    Treatment: Non-Interventional Study

  • Observational group II

    Healthcare providers complete a survey on study.

    Treatment: Non-Interventional Study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
Plain-language title
Studies cannabis use and quality of life in people with multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 February 2026